| Date Filed | Type | Description |
| 10/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/21/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 07/31/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/25/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/24/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 869,565 shares
@ $5.75, valued at
$5M
|
|
| 05/15/2023 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 05/08/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 83,459 shares
@ $2.75, valued at
$229.5k
Bought 312,991 shares
@ $2.75, valued at
$860.7k
Bought 83,459 shares
@ $2.75, valued at
$229.5k
Bought 490,512 shares
@ $2.82, valued at
$1.4M
Bought 490,511 shares
@ $2.82, valued at
$1.4M
|
|
| 05/02/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 60,998 shares
@ $2.55, valued at
$155.5k
Bought 228,754 shares
@ $2.55, valued at
$583.3k
Bought 60,997 shares
@ $2.55, valued at
$155.5k
Bought 124,544 shares
@ $2.62, valued at
$326.3k
Bought 467,068 shares
@ $2.62, valued at
$1.2M
Bought 124,545 shares
@ $2.62, valued at
$326.3k
Bought 58,826 shares
@ $2.67, valued at
$157.1k
Bought 220,610 shares
@ $2.67, valued at
$589k
Bought 58,826 shares
@ $2.67, valued at
$157.1k
|
|
| 04/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 02/23/2023 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Granted 550,000 shares
@ $0
Granted 550,000 shares
@ $0 |
|
| 02/14/2023 |
SC 13G/A
| ORBIMED CAPITAL LLC reports a 0% stake in Milestone Pharmaceuticals, Inc. |
| 11/14/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 08/15/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 07/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/16/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 04/08/2022 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Arcutis Biotherapeutics, Inc.|
Txns:
| Sold 162,000 shares
@ $20.69, valued at
$3.4M
Sold 171,204 shares
@ $20.69, valued at
$3.5M
Sold 167,800 shares
@ $20.66, valued at
$3.5M
Sold 177,196 shares
@ $20.66, valued at
$3.7M
Sold 97,200 shares
@ $20.71, valued at
$2M
Sold 102,800 shares
@ $20.71, valued at
$2.1M
|
|
| 03/31/2022 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on PMV Pharmaceuticals, Inc.|
Txns:
| Sold 365,000 shares
@ $21.52, valued at
$7.9M
Sold 75,000 shares
@ $22.39, valued at
$1.7M
Sold 34,500 shares
@ $21.17, valued at
$730.4k
|
|
| 02/15/2022 |
4
| ORBIMED ADVISORS LLC (Director) has filed a Form 4 on Kinnate Biopharma Inc.|
Txns:
| Bought 156,000 shares
@ $10.22, valued at
$1.6M
Bought 20,700 shares
@ $9.98, valued at
$206.6k
Bought 10,000 shares
@ $9.89, valued at
$98.9k
Bought 9,000 shares
@ $9.96, valued at
$89.6k
|
|
| 02/14/2022 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 02/11/2022 |
SC 13G
| ORBIMED CAPITAL LLC reports a 6.9% stake in SI-BONE, Inc. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2022 |
SC 13G
| ORBIMED CAPITAL LLC reports a 7% stake in Cybin Inc. |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/28/2022 |
4
| ORBIMED ADVISORS LLC (10% Owner) has filed a Form 4 on Sierra Oncology, Inc.|
Txns:
| Exercised (in-or-at-the-money) 374,962 options to buy
@ $13.2, valued at
$4.9M
Exercised (in-or-at-the-money) 56,244 options to buy
@ $13.2, valued at
$742.4k
Exercised (in-or-at-the-money) 56,244 options to buy
@ $13.2, valued at
$742.4k
|
|
| 11/15/2021 |
13F-NT
| Form 13F-NT - Quarterly report filed by institutional managers, Notice: |
| 09/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/25/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|